Plain-English translation of NCT06819891 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called can help control moderately to severely active Crohn's disease in people who haven't had good results with other treatments. The medication is given as an initial intravenous (IV) infusion followed by regular injections under the skin. Researchers will compare this new treatment to a placebo (inactive dummy medication) to see if it safely reduces inflammation and improves symptoms.
Many people with Crohn's disease don't respond well enough to existing treatments or stop responding over time, leaving them with ongoing pain, diarrhea, and inflammation. This trial is testing whether this new medication can offer a better option for these patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll receive an initial IV infusion of either the new medication or a placebo, followed by regular injections under your skin. You'll attend multiple visits at the research center for monitoring, blood tests, and follow-up evaluations to track how the treatment is working and any side effects. The study is designed to assess both how well the medication reduces your Crohn's symptoms and whether it is safe.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States